1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6ED011B0264A950B385256B9600673CB2
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-effective-structures-for-patient-advocacy-relations?opendocument
18
19opendocument
203.87.147.184
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Building Effective Structures for Patient Advocacy Relations

DB Image

ID: 4261


Features:

Metrics, Graphics


Words: 3,000


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
As patient advocacy groups become more sophisticated, successful companies are developing formalized structures designed to meet the needs of these key stakeholders. Many companies are moving toward centralized departments for patient advocacy relations at the affiliate or corporate level.

This 12-page document describes how to build effective structures for patient advocacy relations functions through the practices of leading pharmaceutical companies.

Key topic areas covered in this document include:
-Strategy
-Allocation of Funds
-Group Management
-Building Trust
-Communication
-Coordination among franchises and brand teams

Companies can use this information to make the professional and advocacy relations functions successful by aligning the functions with strategies for thought leader management, public relations and marketing.

Key findings include:
- Assign PAR employees dual group and brand ownership responsibilities to balance internal needs with external demands.
- Leverage field representatives to establish relationship ownership with regional and local professional and advocacy groups.
- Allocate funding to the PAR function to invest in ongoing PAR activities that promote portfolios and the company as a whole

This research originated from a Best Practices, LLC consulting project for a pharmaceutical client. The research was based on interviews with executives from ten pharmaceutical companies.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Medical Device


Companies Profiled:
Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.